Brief: Greenwich Lifesciences Announces Removal Of Clinical Hold Permitting Phase III Clinical Trial To Proceed
12/07/2022 12:45
July 12 (Reuters) - Greenwich Lifesciences Inc GLSI.O :
* GREENWICH LIFESCIENCES ANNOUNCES REMOVAL OF CLINICAL HOLD
PERMITTING PHASE III CLINICAL TRIAL TO PROCEED
* GREENWICH LIFESCIENCES INC - HAS BEGUN SITE INITIATION
VISITS
AND WILL PROVIDE FURTHER UPDATES ON PROGRESS OF FLAMINGO-01 IN
FUTURE
Source text for Eikon: ID:nBwbLbxPRa
Further company coverage: GLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio